POSSIBILITY OF NOVEL ORAL ANTICOAGULANTS USAGE DURING ABLATION IN ATRIAL FIBRILLATION
https://doi.org/10.15829/1560-4071-2014-12-85-95
Abstract
The review provides the data on contemporary approaches to anticoagulant therapy during catheter radiofrequency ablation of atrial fibrillation. The opportunities are discussed for various types of periprocedural use of warfarin, and the results mentioned for the efficacy and safety of novel oral anticoagulants in catheter ablation.
About the Authors
B. A. Tatarsky
Federal Medical Research Centre named after. V. A. Almazov, Saint-Petersburg
Russian Federation
Russian Federation
R. E. Batalov
Scientific-Research Institute of Cardiology, Tomsk
Russian Federation
Russian Federation
S. V. Popov
Scientific-Research Institute of Cardiology, Tomsk
Russian Federation
Russian Federation
References
1. Wolf P, Abbott R, Kannel W. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–88.
2. Camm J, Up G, De Caterina R, et al. Atrial fibrillation (management of) 2010 and focused update (2012), ESC clinical practice guidelines. Eur Heart J 2012;33:2719-47.
3. Calkins H, Kuck K, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace 2012;14:528–606.
4. Kneeland P, Fang M. Trends in catheter ablation for atrial fibrillation in the United States. J Hosp Med. 2009;4:E1–E5.
5. Hart R, Benavente O, McBride R. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492.
6. Smerli G, Lynch S, Fertel S, et al. The difficulties in anticoagulation therapy with warfarin. J Thromb Thrombolysis 2009;27(3):293-9.
7. Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients. International journal of Cardiology 2012;34(5):176-185.
8. Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012;126:2381-91.
9. Mardigyan V, Verma A, Birnie D, et al. Anticoagulation Management Preand Post-AF ablation: A survey of Canadian centers. Can J Cardiol. 2012;29:219–23.
10. Tapanainen J, Braunschweig R, Schwieler J, et al. Continuous warfarin therapy is sate and feasible in catheter ablation of atrial fibrillation. Scand Cardiovasc J 2013;47(2):109-13.
11. Birnie D, Healey J, Wells G, et al. BRUISE CONTROL Investigators. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med. 2013;368:2084–93.
12. Di Biase L, Bunkhardt J, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010;121:2550–56.
13. Santangeli P, Di Biase L, Horton R, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: Evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012;5:302–11.
14. Periprocedural stroke and bleeding complications in patents undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation 2014;129{25):2638-44.
15. Healey J, Eikelboom J, Douketis J. Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012:126:343-348.
16. Diagnostics and treatment of atrial fibrillation. In: The Recommendations of the Russian Society of Cardiology, Pan-Russian Scientific Society of Clinical Electrophysiology, Arrhythmology and Cardiac Pacing, and the Association of Cardiovascular Surgeons of Russia. Moscow. 2012. 100 pp. Russian (Диагностика и лечение фибрилляции предсердий: рекомендации РКО. ВНОА и АССХ. М., 2012. 100 с.)
17. Heidbuchel H, Verhamme R, Alings M, et al. EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34(27):2094-106.
18. Lakkireddy D, Reddy Y, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012;59(13):1168-74.
19. Winkle R, Mead H, Engel G et al. Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Ablation for Atrial Fibrillation. J Am Coll Cardiol 2012;60(12): 1118-19.
20. Kim J, She F, Jongnarangsin K, et al. Dabigatran vs. warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2012;10:483–9.
21. Pandya B, Schwartz L, Shah N, et al. Does Pre-procedural Dabigatran The Need Of Higher Heparin Dosage During Atrial Fibrillation Ablation Procedure? Poster Session VI, Heart Rhythm,2013.
22. Nin T, Sairaku A, Yoshida Y et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing Clin Electrophysiol. 2013;36:172–9.
23. Bassiouny M, Saliba W, Rickard J, et al. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6:460–6.
24. Arshad A, Buch E, Hamam I, et al. Comparative safety of anticoagulation strategies periablation for atrial fibrillation: Data from a large multicenter study. Heart Rhythm 2013, Abstract #AB33-02.
25. Providencia R, Albenque J, Combes S, et al. Safety and efficacy of dabigatran versus warfarin in patients undergoing catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Heart 2014;100:324–35.
26. Hohnloser S, Camm J. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15(10):1407-11.
27. Di Biase L, Burkhardt D, Gilbert G, et al. Dabigratan Has a Higher Risk of Left Atrial Appendage Thrombus Formation in Patients With Af When Compared to Warfarin and Rivaroxaban. http://www.abstractsonline.com /Plan/ViewAbstract. Dallas, 2013.
28. Steinberg B, Hasselblad V, Atwater B, et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies.J.Interv.Card. Electrophysiol. 2013; 37:213–21.
29. Kaess B, Ammar S, Reents T, et al. Comparison of Safety of Left Atrial Catheter Ablation Procedures for Atrial Arrhythmias under Continuous Anticoagulation with Apixaban versus Phenprocoumon. Published Online: October 11, 2014.
30. Lakkireddy D, Reddy M, Swarup V, et al. Uninterrupted rivaroxaban vs. warfarin for periprocedural anticoagulation during atrial fibrillation ablation: A multicentre experience. Heart Rhythm 2013, Abstract #AB33-01.
31. Dillier R, Ammar S, Reents T et al. Safety and Efficacy of Continuous Periprocedural Rivaroxaban for Patients Undergoing Catheter Ablation Procedures: A Retrospective Registry Analysis. Heart Rhythm, 2013, Abstract #PO03-127.
32. Lakkireddy D, Reddy Y, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective study. J Am Coll Cardiol. 2014;63:982–8.
33. Providencia R, Marijon E, Albenque J-P, et al. Rivaroxaban and Dabigatran in Patients Undergoing Catheter Ablation of Atrial Fibrillation. Europace. 2014;16(8):1137-44.
34. Siklody C, Deneke T, Hocini M, et al. Incidence of asymptomatic intracranial embolic events after pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a multicenter study. J Am Coll Cardiol. 2011;58(7):681-8.
35. Haines D, Stewart M, Dahlberg S, et al. Microembolism and catheter ablation I: A comparison of irrigated radiofrequency and multielectrode-phased radiofrequency catheter ablation of pulmonary vein ostia. Circ Arrhythm Electrophysiol 2013; 6:16–22.
36. Bohnen M, Stevenson W, Tedrow U, et al. Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias. Heart Rhythm. 2011;8:1661–66.
37. Nagy-Balo E, Tint D, Clemens M, et al. Transcranial measurement of cerebral microembolic signals during pulmonary vein isolation: a comparison of two ablation techniques. Circ Arrhythm Electrophysiol. 2013;6:473–80.
38. Ichiki H, Oketani N, Ishida S, et al. The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran. Pacing and Clinical Electrophysiology 2013;36(111):1328-35.
Review
For citations:
Tatarsky B.A., Batalov R.E., Popov S.V. POSSIBILITY OF NOVEL ORAL ANTICOAGULANTS USAGE DURING ABLATION IN ATRIAL FIBRILLATION. Russian Journal of Cardiology. 2014;(12):85-95. (In Russ.) https://doi.org/10.15829/1560-4071-2014-12-85-95
Views:
649
Email this article 